Marker Therapeutics, Inc. MRKR

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker's Multi Antigen Recognizing ("MAR")-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient's/donor's blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor targets via native T cell receptors ("TCR"), while limiting tumor adaptation/escape by antigen-negative selection or antigen down-regulation. When infused into a patient with cancer, the MAR-T cells are designed to kill cancer cells expressing the TAA.

Last close 0.96 2026-10-23
Market cap $16.0M 2026-06-30 share count
52-week range 0.84 - 2.46

Valuation FY2025 figures against the last close

P/S4.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.79

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.5M$6.6M$3.3M$3.5M$1.2M$466.8K$213.2K$206.0K$183.1K—
R&D $11.8M$13.5M$10.4M$12.0M$27.8M$18.9M$12.8M$8.0M$5.3M$3.8M
SG&A $4.2M$4.2M$7.5M$11.3M$12.9M$10.5M$10.0M$24.4M$6.4M$4.7M
Total operating expenses $16.4M$17.7M$17.9M$23.3M$40.7M$29.4M$22.7M$148.4M$11.7M$8.5M
Operating income -$12.9M-$11.1M-$14.6M-$19.8M-$39.5M-$28.9M-$22.5M-$148.2M-$11.5M-$8.5M
Pre-tax income -$12.2M-$10.7M-$14.0M-$19.8M———-$148.0M-$11.0M-$2.5M
Income tax $15.2K$50.0K$3.7K————$0$0$0
Net income -$12.2M-$10.7M-$8.2M-$29.9M-$41.9M-$28.7M-$21.4M-$148.0M-$11.0M-$2.5M
EPS, basic -0.79-1.19-0.94-3.58-5.47-0.61——-1.16-0.36
EPS, diluted -0.79-1.19-0.94-3.58-5.47-0.61-0.47-7.75-1.16-0.72
Shares, diluted (wtd. avg.) 15.3M9.0M8.8M8.4M7.7M47.0M45.6M19.1M9.5M7.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $16.1M$19.2M$15.1M$11.8M$43.5M$21.4M$43.9M$61.7M$5.1M—
Total current assets $19.1M$22.0M$17.1M$16.6M$46.0M$24.4M$45.5M$62.0M$5.2M$7.9M
Property, plant and equipment ———$12.3M$12.3M$10.4M$418.0K$147.7K$0—
Total assets $19.1M$22.0M$17.1M$34.4M$68.1M$45.6M$46.4M$62.1M$5.2M$7.9M
Accounts payable $793.7K$1.1M$961.0K$1.1M$5.1M$2.9M$993.0K$1.6M$1.0M$680.0K
Total current liabilities $2.3M$3.5M$3.1M$7.8M$12.9M$6.4M$2.0M$2.8M$1.5M$1.7M
Total liabilities $2.3M$3.5M$3.1M$14.8M$24.1M$18.3M$2.3M$2.8M$1.5M$1.7M
Retained earnings -$459.2M-$447.0M-$436.3M-$428.0M-$398.1M-$356.2M-$327.5M-$306.1M-$157.4M-$145.8M
Total equity $16.8M$18.6M$14.1M$19.6M$44.0M$27.3M$44.1M$59.3M$3.7M$6.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$12.0M-$10.9M-$16.4M-$27.0M-$27.3M-$20.0M-$18.3M-$14.5M-$8.4M-$6.5M
Depreciation and amortisation ———$2.8M$2.1M$485.6K$105.1K———
Stock-based compensation $537.5K$245.9K$858.3K$3.3M$6.0M$5.2M$5.4M$16.4M$2.7M$1.6M
Capital expenditure ——————$375.0K$147.7K$0—
Investing cash flow ——$18.7M-$4.9M-$3.1M-$9.3M-$375.0K-$147.7K$0—
Financing cash flow $9.9M$15.0M$1.1M$202.1K$52.6M$6.7M$816.5K$71.2M$5.7M$7.8M
Buybacks ———————$71.7K$310.5K$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-031274.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -150M -100M -50M 0 50M Net income, FY2016: -2.5M Revenue, FY2017: 183.1K Net income, FY2017: -11M Revenue, FY2018: 206K Net income, FY2018: -148M Revenue, FY2019: 213.2K Net income, FY2019: -21.4M Revenue, FY2020: 466.8K Net income, FY2020: -28.7M Revenue, FY2021: 1.2M Net income, FY2021: -41.9M Revenue, FY2022: 3.5M Net income, FY2022: -29.9M Revenue, FY2023: 3.3M Net income, FY2023: -8.2M Revenue, FY2024: 6.6M Net income, FY2024: -10.7M Revenue, FY2025: 3.5M Net income, FY2025: -12.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $183.1K $206.0K $213.2K $466.8K $1.2M $3.5M $3.3M $6.6M $3.5M
Gross profit — — — — — — — — — —
Net income -$2.5M -$11.0M -$148.0M -$21.4M -$28.7M -$41.9M -$29.9M -$8.2M -$10.7M -$12.2M

Recent filings and events

  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%